Belenos Biosciences

Executive Summary

Belenos Biosciences is a private clinical-stage biopharmaceutical company headquartered in San Diego, CA, focused on developing bispecific therapeutics for chronic inflammatory diseases. Founded in 2016, the company aims to elevate the standard of care by targeting well-validated disease pathways with the goal of achieving durable clinical remission. Its lead asset is a novel bispecific antibody designed to simultaneously modulate two key inflammatory drivers, potentially offering improved efficacy and durability over existing treatments for conditions such as COPD, asthma, and atopic dermatitis. The company's approach leverages the synergistic effects of dual targeting to address the complex pathophysiology of these disorders, with the ambition of delivering meaningful, long-lasting outcomes for patients.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line data readout for lead bispecific candidate in COPD or asthma65% success
• Q2 2026Announcement of strategic partnership or licensing deal for non-U.S. rights50% success
• Q3 2026Initiation of Phase 3 trial for atopic dermatitis indication70% success